Mustang Bio, Inc. (MBIO) Insider Trading Activity

NASDAQ$0.8963
Market Cap
$6.54M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
396 of 883
Rank in Industry
235 of 506

MBIO Insider Trading Activity

MBIO Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$238
1
33
Sells
$241
2
67

Related Transactions

Jin Daviddirector
1
$238
0
$0
$238
Chill Adam J.director
0
$0
1
$4
$-4
Herskowitz Neildirector
0
$0
1
$238
$-238

About Mustang Bio, Inc.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Insider Activity of Mustang Bio, Inc.

Over the last 12 months, insiders at Mustang Bio, Inc. have bought $238 and sold $241 worth of Mustang Bio, Inc. stock.

On average, over the past 5 years, insiders at Mustang Bio, Inc. have bought $136,194 and sold $13,267 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Jin David (director) — $238.

The last purchase of 247 shares for transaction amount of $238 was made by Jin David (director) on 2025‑12‑30.

List of Insider Buy and Sell Transactions, Mustang Bio, Inc.

2025-12-30SaleChill Adam J.director
4
<0.0001%
$0.95
$4
+4.93%
2025-12-30SaleHerskowitz Neildirector
247
0.0034%
$0.96
$238
+4.93%
2025-12-30PurchaseJin Daviddirector
247
0.0034%
$0.96
$238
+4.93%
2022-09-13PurchaseLitchman Manuel MDdirector
5,000
0.0041%
$0.52
$2,582
-30.68%
2022-09-13PurchaseROSENWALD LINDSAY A MDdirector
5,000
0.0041%
$0.52
$2,582
-30.68%
2022-03-18PurchaseLitchman Manuel MDdirector
5,000
0.0041%
$0.74
$3,695
-34.11%
2022-03-18PurchaseROSENWALD LINDSAY A MDdirector
4,094
0.0034%
$0.74
$3,025
-34.11%
2021-12-14SaleAchenbach BrianSVP, Fin. & Corp. Controller
4,374
0.0003%
$1.83
$8,004
-62.80%
2021-10-27PurchaseLitchman Manuel MDPresident and CEO
65,000
0.0048%
$2.24
$145,600
-65.88%
2021-10-12SaleAchenbach BrianSVP, Fin. & Corp. Controller
4,450
0.0003%
$2.28
$10,146
-64.93%
2021-07-30PurchaseLitchman Manuel MDPresident and CEO
86,206
0.0063%
$2.91
$250,859
-59.52%
2021-04-09SaleAchenbach BrianSVP, Fin. & Corp. Controller
2,423
0.0002%
$3.36
$8,141
-22.88%
2021-03-05PurchaseLitchman Manuel MDPresident and CEO
165,562
0.0135%
$3.12
$516,553
-12.46%
2020-12-15PurchaseLitchman Manuel MDPresident and CEO
100,000
0.0114%
$2.91
$291,000
+2.69%
2020-12-14PurchaseROSENWALD LINDSAY A MDdirector
100,000
0.0115%
$2.66
$266,000
+12.96%
2020-12-08SaleAchenbach BrianSVP, Fin. & Corp. Controller
5,185
0.0006%
$3.03
$15,711
-1.29%
2020-10-21SaleAchenbach BrianSVP, Fin. & Corp. Controller
3,056
0.0004%
$2.97
$9,076
+11.39%
2020-06-11PurchaseLitchman Manuel MDPresident and CEO
153,846
0.0228%
$3.25
$500,000
+0.15%
2020-05-22SaleLitchman Manuel MDPresident and CEO
12,373
0.0018%
$3.04
$37,614
+5.84%
2020-05-22SaleAchenbach BrianSVP, Fin. & Corp. Controller
880
0.0001%
$3.04
$2,675
+5.84%
Total: 34
*Gray background shows transactions not older than one year

Insider Historical Profitability

5.27%
Chill Adam J.director
375
0.0051%
$336.1101
Jin Daviddirector
286
0.0039%
$256.3410
Herskowitz Neildirector
145
0.002%
$129.9611
Litchman Manuel MDdirector
1098987
15.0565%
$985,022.05141
+1.42%
ROSENWALD LINDSAY A MDdirector
299181
4.0989%
$268,155.9340
+12.96%
Achenbach BrianSVP, Fin. & Corp. Controller
144729
1.9828%
$129,720.6038
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$13,664,154
40
-70.35%
$6.22M
$1,029,337
36
-28.38%
$7.83M
$29,635,355
27
9.05%
$5.68M
$63,749,694
24
-12.24%
$8.06M
$1,039,491
21
-11.76%
$6.84M
$742,412
14
-50.36%
$5.93M
$684,058
11
-57.59%
$5.1M
$188,726
11
-28.87%
$8.17M
$405,510
11
-46.23%
$6.41M
$120,379
10
-24.48%
$7.28M
$8,971,546
8
6.18%
$5.37M
$211,895
8
-39.70%
$7.03M
$159,974
7
-18.60%
$6.45M
$76,299
4
11.60%
$4.98M
$1,184,658
4
-22.17%
$7.38M
Mustang Bio, Inc.
(MBIO)
$1,057,000
3
5.27%
$6.54M
$28,395
3
3.48%
$7.97M
$31,190
2
-14.18%
$6.9M
$4,423
2
3.27%
$4.85M

MBIO Institutional Investors: Active Positions

Increased Positions12+57.14%284,301+101.31%
Decreased Positions6-28.57%12,981-4.63%
New Positions6New225,698New
Sold Out Positions3Sold Out12,431Sold Out
Total Postitions27+28.57%551,955+96.68%

MBIO Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Blackrock, Inc.$91.001.41%84,745+83,080+4,989.79%2025-09-30
Kestra Advisory Services, Llc$71.001.1%66,108+66,108New2025-09-30
Vanguard Group Inc$62.000.96%57,863+57,863New2025-09-30
Geode Capital Management, Llc$28.000.44%26,418+10,336+64.27%2025-09-30
Xtx Topco Ltd$20.000.31%18,775+18,775New2025-09-30
Renaissance Technologies Llc$13.000.2%11,800+11,800New2025-09-30
Cfo4life Group, Llc$11.000.17%10,461+10,461New2025-09-30
Sbi Securities Co., Ltd.$2.000.03%2,007+1,505+299.8%2025-09-30
Tower Research Capital Llc (Trc)$1.000.02%1,332-2,646-66.52%2025-09-30
Citigroup Inc$1.000.01%602-404-40.16%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.